{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:06:59Z","timestamp":1787753219352,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,30]]},"DOI":"10.7759\/cureus.57291","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T02:08:15Z","timestamp":1711850895000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Pregnancy and Fetal Outcomes Following Brentuximab Vedotin for Early Relapsed Classic Hodgkin Lymphoma After Autologous Stem Cell Transplant"],"prefix":"10.7759","author":[{"given":"Akari","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisa","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Kobune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000252","article-title":"The care of adolescents and young adults with cancer: results of the ESMO\/SIOPE survey","volume":"2","author":"Saloustros E","year":"2017","unstructured":"Saloustros E, Stark DP, Michailidou K, et al.. The care of adolescents and young adults with cancer: results of the ESMO\/SIOPE survey. ESMO Open. 2017, 2:e000252. 10.1136\/esmoopen-2017-000252","journal-title":"ESMO Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer DA","year":"2018","unstructured":"Eichenauer DA, Aleman BM, Andre M, et al.. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018, 29:19-29. 10.1093\/annonc\/mdy080","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma","volume":"12","author":"Majhail NS","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, et al.. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006, 12:1065-72. 10.1016\/j.bbmt.2006.06.006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.020","article-title":"Outcomes of Hodgkin\u2019s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation","volume":"18","author":"Kaloyannidis P","year":"2012","unstructured":"Kaloyannidis P, Voutiadou G, Baltadakis I, et al.. Outcomes of Hodgkin\u2019s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012, 18:451-7. 10.1016\/j.bbmt.2011.07.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Martinez C","year":"2013","unstructured":"Martinez C, Canals C, Sarina B, et al.. Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013, 24:2430-4. 10.1093\/annonc\/mdt206","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase \u2161 study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes A","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, et al.. Results of a pivotal phase \u2161 study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012, 30:2183-9. 10.1200\/JCO.2011.38.0410","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen R","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, et al.. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016, 128:1562-6. 10.1182\/blood-2016-02-699850","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/BF02986620","article-title":"Pilot phase I\/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma","volume":"77","author":"Ogura M","year":"2003","unstructured":"Ogura M, Kagami Y, Taji H, Suzuki R, Miura K, Takeuchi T, Morishima Y. Pilot phase I\/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematologists. 2003, 77:503-11. 10.1007\/BF02986620","journal-title":"Int J Hematologists"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump M","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, et al.. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014, 32:3490-6. 10.1200\/JCO.2013.53.9593","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler Y","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, et al.. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Our Heart J. 2015, 36:2921-64. 10.1093\/eurheartj\/ehv318","journal-title":"Our Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz CH","year":"2004","unstructured":"Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease. Br J Haematol. 2004, 124:645-52. 10.1111\/j.1365-2141.2003.04828.x","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00360-4","article-title":"Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches","volume":"11","author":"Hanel W","year":"2022","unstructured":"Hanel W, Herrera AF, Epperla N. Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. Exp Hematol Oncol. 2022, 11:108. 10.1186\/s40164-022-00360-4","journal-title":"Exp Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani RH","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, et al.. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021, 138:427-38. 10.1182\/blood.2020009178","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz CH","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, et al.. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015, 385:1853-62. 10.1016\/S0140-6736(15)60165-9","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz CH","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, et al.. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018, 132:2639-42. 10.1182\/blood-2018-07-861641","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216291","article-title":"Overactivation or apoptosis: which mechanisms affect chemotherapy-induced ovarian reserve depletion?","volume":"24","author":"Kashi O","year":"2023","unstructured":"Kashi O, Meirow D. Overactivation or apoptosis: which mechanisms affect chemotherapy-induced ovarian reserve depletion?. Int J Mol Sci. 2023, 24:16291. 10.3390\/ijms242216291","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005557","article-title":"Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine","volume":"7","author":"Machet A","year":"2023","unstructured":"Machet A, Poudou C, Tomowiak, et al.. Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine. Blood Adv. 2023, 7:3978-83. 10.1182\/bloodadvances.2021005557","journal-title":"Blood Adv"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage \u2162 or \u2163 Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell SM","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, et al.. Overall survival with brentuximab vedotin in stage \u2162 or \u2163 Hodgkin\u2019s lymphoma. N Engl J Med. 2022, 387:310-20. 10.1056\/NEJMoa2206125","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31732","article-title":"Pregnancy after cancer: does timing of conception affect infant health?","volume":"124","author":"Hartnett KP","year":"2018","unstructured":"Hartnett KP, Merten AC, Kramer MR, Lash TL, Spencer JB, Ward KC, Howards PP. Pregnancy after cancer: does timing of conception affect infant health?. Cancer. 2018, 124:4401-7. 10.1002\/cncr.31732","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/227165-successful-pregnancy-and-fetal-outcomes-following-brentuximab-vedotin-for-early-relapsed-classic-hodgkin-lymphoma-after-autologous-stem-cell-transplant","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T02:08:20Z","timestamp":1711850900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/227165-successful-pregnancy-and-fetal-outcomes-following-brentuximab-vedotin-for-early-relapsed-classic-hodgkin-lymphoma-after-autologous-stem-cell-transplant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.57291","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,30]]}}}